CA2373643A1 - Agents anti-tumorales contenant des composes de boroproline - Google Patents

Agents anti-tumorales contenant des composes de boroproline Download PDF

Info

Publication number
CA2373643A1
CA2373643A1 CA002373643A CA2373643A CA2373643A1 CA 2373643 A1 CA2373643 A1 CA 2373643A1 CA 002373643 A CA002373643 A CA 002373643A CA 2373643 A CA2373643 A CA 2373643A CA 2373643 A1 CA2373643 A1 CA 2373643A1
Authority
CA
Canada
Prior art keywords
agent
cancer
administered
carcinoma
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373643A
Other languages
English (en)
Inventor
Barbara P. Wallner
Glenn Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Point Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2373643A1 publication Critical patent/CA2373643A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement de patients sujets à une prolifération cellulaire anormale. Cette méthode consiste à administrer aux patients nécessitant un tel traitement, une quantité efficace d'un agent de formule (I), pour inhiber la prolifération cellulaire telle celle liée à une croissance tumorale ou à une métastase. Ladite invention a également trait à une méthode d'inhibition d'une angiogenèse dans une masse cellulaire proliférant anormalement, en administrant un agent de formule (I). Les composés préférés sont des dérivés de boroproline.
CA002373643A 1999-05-25 2000-05-25 Agents anti-tumorales contenant des composes de boroproline Abandoned CA2373643A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13586199P 1999-05-25 1999-05-25
US60/135,861 1999-05-25
PCT/US2000/014505 WO2000071135A1 (fr) 1999-05-25 2000-05-25 Agents anti-tumorales contenant des composes de boroproline

Publications (1)

Publication Number Publication Date
CA2373643A1 true CA2373643A1 (fr) 2000-11-30

Family

ID=22470056

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373643A Abandoned CA2373643A1 (fr) 1999-05-25 2000-05-25 Agents anti-tumorales contenant des composes de boroproline

Country Status (6)

Country Link
EP (1) EP1187619A1 (fr)
JP (1) JP2003500360A (fr)
AU (1) AU781897B2 (fr)
CA (1) CA2373643A1 (fr)
HK (1) HK1046846A1 (fr)
WO (1) WO2000071135A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
IL155273A0 (en) 2000-10-12 2003-11-23 Pharma Mar Sa Pharmaceutical compositions comprising an aplidine compound
WO2003037373A1 (fr) * 2001-10-31 2003-05-08 Medical Research Council Utiilisation d'un antagoniste du recepteur ep2 ou ep4 et/ou d'un inhibiteur de la cox-1 pour traiter un cancer cervical
CA2468192A1 (fr) 2001-11-26 2003-06-05 Trustees Of Tufts College Inhibiteurs peptidomimetiques d'enzymes de clivage post-proline
JP2003267966A (ja) * 2002-03-13 2003-09-25 Pola Chem Ind Inc フラバン誘導体、皮膚線維芽細胞増殖抑制剤および皮膚外用剤
JP2006506442A (ja) * 2002-07-09 2006-02-23 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物併用療法
SI1603584T1 (sl) 2003-03-12 2009-02-28 Dana Farber Cancer Inst Inc Aplidin za zdravljenje multiple mieloma
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2146210A1 (fr) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
WO2012135570A1 (fr) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (fr) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012145603A1 (fr) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
CN106075450A (zh) * 2011-11-22 2016-11-09 塔夫茨大学信托人 用于树突状细胞癌症疫苗的小分子增强剂
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
JP2018507914A (ja) 2015-03-09 2018-03-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
EP3515470B1 (fr) * 2016-09-21 2023-06-14 Agency for Science, Technology and Research Procédés pour prédire une inflammation cutanée et déterminer une susceptibilité au cancer
MX2019011867A (es) 2017-04-03 2020-01-09 Coherus Biosciences Inc Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.
CN115779148B (zh) * 2021-09-09 2024-02-23 中国科学院福建物质结构研究所 一种牙种植体表面涂层及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02268118A (ja) * 1989-04-07 1990-11-01 Mitsubishi Gas Chem Co Inc 免疫賦活剤
US5328936A (en) * 1993-02-01 1994-07-12 Rohm And Haas Company Polymerization process for making porous polymeric particles
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5767242A (en) * 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV
WO1999062914A1 (fr) * 1998-06-05 1999-12-09 Point Therapeutics, Inc. Composes cycliques de boroproline
AU5480199A (en) * 1998-08-21 2000-03-14 Point Therapeutics, Inc. Regulation of substrate activity

Also Published As

Publication number Publication date
HK1046846A1 (zh) 2003-01-30
EP1187619A1 (fr) 2002-03-20
WO2000071135A1 (fr) 2000-11-30
JP2003500360A (ja) 2003-01-07
AU781897B2 (en) 2005-06-23
AU5292700A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
US6949514B2 (en) Anti-tumor agents
AU781897B2 (en) Anti-tumor comprising boroproline compounds
US10174077B2 (en) Method of inhibiting activity of cell surface fibroblast activation protein alpha
US20230310354A1 (en) Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
US20050267027A1 (en) Use of erythropoietin for treatment of cancer
WO2006050162A2 (fr) Dérivés d'imidazole
US10155789B2 (en) Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof
WO2021007094A1 (fr) Peptides d'endostatine pour le traitement de tumeurs, d'une fibrose et d'une lésion pulmonaire aiguë
US8232318B2 (en) Approaches to treat cancer using HB-EGF inhibitors
EP1806138A1 (fr) Agents anti-tumoraux comprenant des dérivés de la boroproline
AU2005211682A1 (en) Anti-tumor comprising boroproline compounds
WO2007059099A2 (fr) Polytherapie a base de composes de boroproline contre le cancer
US20240216465A1 (en) Method for treating refractory brain tumor
WO2022271822A1 (fr) Compositions et méthodes pour accroître l'efficacité d'immunothérapies et de vaccins
WO2023010141A1 (fr) Ciblage simultané de voies oncogènes pour améliorer la chimiothérapie et l'immunothérapie
CA3230917A1 (fr) Peptides d'endostatine pour le traitement de tumeurs, d'une fibrose et d'une lesion pulmonaire aigue
US20070243164A1 (en) Treating Skin Cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead